Profile data is unavailable for this security.
About the company
Nippon Shinyaku Co., Ltd. is a Japan-based company principally involved in the manufacture and sale of pharmaceutical products and functional foodstuffs. The Company operates in two business segments. The Pharmaceutical segment is involved in the manufacture and sale of urinary system therapeutic agents, blood cancer therapeutic agents, pain, inflammation and allergic therapeutic agents, digestive system therapeutic agents, cardiovascular systems and metabolic therapeutic agents. The Functional Foodstuff segment involves in the manufacture and sale of health food materials, quality stability preservatives, protein preparation, spice and seasoning products. The Company is also involved in the business support business, non-life insurance agency business, as well as the provision of real estate leasing services.
- Revenue in JPY (TTM)146.98bn
- Net income in JPY24.14bn
- Incorporated1919
- Employees2.19k
- LocationNippon Shinyaku Co Ltd14, Nishinosho Monguchi-cho,Kisshoin, Minami-kuKYOTO-SHI 601-8550JapanJPN
- Phone+81 753211111
- Fax+81 753210678
- Websitehttps://www.nippon-shinyaku.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KAKEN PHARMACEUTICAL CO., LTD. | 72.10bn | 2.97bn | 159.78bn | 1.13k | 44.51 | 0.9399 | 27.95 | 2.22 | 78.14 | 78.14 | 1,915.49 | 3,700.49 | 0.429 | 1.86 | 2.89 | 63,801,770.00 | 1.76 | 8.17 | 2.00 | 9.56 | 53.89 | 55.55 | 4.11 | 16.09 | 4.68 | -- | 0.0267 | 44.04 | -4.01 | -5.81 | -43.03 | -22.17 | 3.16 | 0.00 |
| Kissei Pharmaceutical Co Ltd | 73.72bn | 12.20bn | 180.23bn | 1.80k | 13.71 | 0.8266 | 10.89 | 2.44 | 266.51 | 266.51 | 1,612.29 | 4,421.72 | 0.3213 | 1.68 | 2.60 | 41,067,970.00 | 5.38 | 3.21 | 5.87 | 3.47 | 48.23 | 52.39 | 16.74 | 11.10 | 4.51 | -- | 0.007 | 36.56 | 3.23 | -1.83 | -18.52 | 3.08 | 3.74 | 10.76 |
| Peptidream Inc | 28.71bn | 3.04bn | 259.37bn | 603.00 | 85.14 | 6.41 | 47.43 | 9.03 | 23.43 | 23.43 | 221.37 | 311.32 | 0.4307 | 4.52 | 2.66 | 47,615,580.00 | 4.55 | -- | 5.34 | -- | 59.97 | -- | 10.57 | -- | 2.88 | 2.80 | 0.3551 | -- | 6.93 | -- | -59.81 | -- | -- | -- |
| Sawai Group Holdings Co Ltd | 185.31bn | 17.71bn | 259.75bn | 3.39k | 14.71 | 1.24 | 8.18 | 1.40 | 403.17 | 348.86 | 4,219.61 | 4,800.54 | 0.4905 | 1.32 | 2.75 | 54,615,090.00 | 3.62 | 1.14 | 5.08 | 1.56 | 30.41 | 36.92 | 7.39 | 2.24 | 1.31 | 71.96 | 0.291 | 81.02 | 3.37 | 3.58 | 144.81 | -2.01 | 10.06 | 0.00 |
| Tsumura & Co | 148.79bn | 16.76bn | 287.08bn | 4.03k | 16.97 | 1.05 | 9.81 | 1.93 | 220.44 | 220.44 | 1,954.80 | 3,569.48 | 0.3633 | 0.7326 | 2.27 | 36,903,020.00 | 4.55 | 4.98 | 5.57 | 6.03 | 47.57 | 53.82 | 12.53 | 12.74 | 2.90 | -- | 0.2115 | 30.98 | 8.10 | 3.51 | -12.50 | 2.59 | 6.41 | 0.00 |
| Nippon Shinyaku Co., Ltd. | 146.98bn | 24.14bn | 308.33bn | 2.19k | 12.25 | 1.37 | 10.56 | 2.10 | 358.40 | 358.40 | 2,182.30 | 3,192.25 | 0.6128 | 1.37 | 2.97 | 67,237,880.00 | 10.07 | 10.41 | 11.44 | 12.28 | 64.60 | 59.11 | 16.43 | 15.84 | 4.49 | -- | 0.0094 | 32.10 | 4.87 | 7.28 | -8.70 | 11.98 | 22.93 | 17.00 |
| Hisamitsu Pharmaceutical Co Inc | 141.71bn | 13.97bn | 318.52bn | 2.77k | 20.67 | 1.07 | 16.25 | 2.25 | 180.93 | 180.93 | 1,840.25 | 3,497.04 | 0.441 | 3.13 | 3.43 | -- | 4.49 | 4.22 | 5.25 | 4.82 | 55.73 | 58.62 | 10.18 | 10.03 | 3.76 | -- | 0.0078 | 52.55 | 10.42 | -0.2385 | 18.97 | -6.17 | 28.90 | 0.5989 |
| Kobayashi Pharmaceutical Co Ltd | 173.46bn | 20.34bn | 417.63bn | 3.53k | 20.07 | 1.95 | 15.82 | 2.41 | 268.11 | 268.11 | 2,287.06 | 2,755.17 | 0.6629 | 3.88 | 3.44 | 49,081,780.00 | 7.77 | 8.01 | 9.79 | 10.18 | 55.56 | 56.45 | 11.73 | 12.24 | 2.43 | -- | 0.0048 | 33.19 | 4.33 | 0.7037 | 1.58 | 2.45 | 29.67 | 8.88 |
Data as of May 02 2024. Currency figures normalised to Nippon Shinyaku Co Ltd's reporting currency: Japanese Yen JPY
18.38%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nomura Asset Management Co., Ltd.as of 29 Feb 2024 | 3.10m | 4.42% |
| FIL Investments (Japan) Ltd.as of 29 Feb 2024 | 1.99m | 2.83% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 1.76m | 2.51% |
| BlackRock Fund Advisorsas of 31 Aug 2023 | 1.14m | 1.62% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 1.01m | 1.44% |
| BlackRock Japan Co. Ltd.as of 31 Aug 2023 | 931.80k | 1.33% |
| Schroder Investment Management (Japan) Ltd.as of 31 Dec 2023 | 850.40k | 1.21% |
| Nikko Asset Management Co., Ltd.as of 05 Apr 2024 | 807.30k | 1.15% |
| Daiwa Asset Management Co. Ltd.as of 29 Mar 2024 | 793.60k | 1.13% |
| Sumitomo Mitsui DS Asset Management Co., Ltd.as of 04 Apr 2024 | 521.03k | 0.74% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
